Omicron overpowers key COVID antibody treatments in early tests
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Cameroni, E. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.12.472269 (2021).
Aggarwal, A. et al. Preprint at medRxiv https://doi.org/10.1101/2021.12.14.21267772 (2021).
Planas, D. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.14.472630 (2021).
Cao, Y. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.07.470392 (2021).